These findings demonstrate that the metabolic adaptations conferred by ATG5 deletion are potent and sustained, thereby enabling CAR-T cells to achieve complete and durable tumor clearance in an ovarian cancer model. This evidence concerns the gene ATG5 and ovarian carcinoma.